Market Data
Market Cap₹27,498.49 Cr.
52W High₹24,235.05
Current Price₹21,433.15
52W Low₹11,500
Down from 52W High11.6 %
Face Value₹10
Performance
ROCE33.59 %
ROE26.55 %
EPS (TTM)₹115.1
EPS Prev Qtr₹165.76
EPS Last Year₹75.49
EBITDA Qtr₹196.33 Cr.
Book Value₹1,461
Financial Health
Debt/Equity0.1
Debt/Profit0.39
Total Assets₹2,930.138 Cr.
Dividend Yield0.16 %
Promoter Holding32.62 %
Earning Power22.69 %
Valuation
Stock P/E55.24
Industry P/E33.81
Price to Book14.67
Price to Sales11.59
Graham Number₹3,571.23
Key Metrics
Face Value
₹10
About Neuland Laboratories Ltd
Healthcare · Pharmaceuticals
Neuland Laboratories Ltd is listed on NSE in the Healthcare / Pharmaceuticals sector. Face value ₹10. Market cap ₹27,498.49 Cr.
Price Chart
Strengths & Weaknesses
Strengths
- The company has a strong ROCE of 33.59%, indicating efficient use of capital.
- ROE is at a healthy 26.55%, reflecting good return on shareholders' equity.
- The company maintains a low debt-to-equity ratio of 0.1, suggesting a conservative capital structure.
- Promoter holding stands at 32.62%, indicating significant management control and alignment of interests.
Weaknesses
- The P/E ratio of 61.35 suggests the stock may be overvalued relative to earnings.
- The P/B ratio of 16.29 indicates the market values the company at a premium to its book value.
- The dividend yield is very low at 0.14%, offering limited income to investors.
Peer Comparison
| Name | CMP | P/E | Market Cap | Div Yield | NP Qtr | Qtr Profit Var% | Sales Qtr | Qtr Sales Var% | ROCE% | Debt/Eq |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | - | 36.51 | ₹4,41,477.63 Cr | 0.87% | ₹12,172.7 Cr | - | ₹59,910.52 Cr | - | 18.72% | 0.05 |
| Divis Laboratories Ltd | - | 86.48 | ₹2,53,031.38 Cr | 0.31% | ₹2,925 Cr | - | ₹11,230 Cr | - | 23.04% | 0 |
| Torrent Pharmaceuticals Ltd | - | 77.67 | ₹1,85,216.32 Cr | 0.78% | ₹2,156 Cr | - | ₹15,723 Cr | - | 15.1% | 1.76 |
| Zydus Lifesciences Ltd | - | 27.01 | ₹1,20,897.46 Cr | 0.08% | ₹4,492.2 Cr | - | ₹28,591.7 Cr | - | 16.76% | 0.43 |
| Cipla Ltd | - | 33.28 | ₹1,12,201.64 Cr | 0.94% | ₹3,364.84 Cr | - | ₹28,324.4 Cr | - | 13.24% | 0.01 |
| Laurus Labs Ltd | - | 99.31 | ₹1,08,698.22 Cr | 0.06% | ₹1,090.76 Cr | - | ₹7,269.64 Cr | - | 20.79% | 0.45 |
| Dr Reddys Laboratories Ltd | - | 31.6 | ₹1,02,039.12 Cr | 0.65% | ₹3,183.3 Cr | - | ₹33,227.9 Cr | - | 10.05% | 0.17 |
| Mankind Pharma Ltd | - | 49.29 | ₹1,00,752.43 Cr | 0.04% | ₹2,067.57 Cr | - | ₹14,737.88 Cr | - | 13.95% | 0.38 |
| Aurobindo Pharma Ltd | - | 26.56 | ₹97,814.24 Cr | 0.24% | ₹3,710.8 Cr | - | ₹34,935.29 Cr | - | 12.75% | 0.2 |
| Lupin Ltd | - | 16.64 | ₹94,274.49 Cr | 0.87% | ₹5,550.99 Cr | - | ₹29,966.58 Cr | - | 27.95% | 0.26 |
| Glenmark Pharmaceuticals Ltd | - | 36.67 | ₹65,922.11 Cr | 0.11% | ₹1,797.81 Cr | - | ₹17,736.56 Cr | - | 24.78% | 0.25 |
| Alkem Laboratories Ltd | - | 28.65 | ₹61,804.34 Cr | 1.03% | ₹2,206.3 Cr | - | ₹15,081.28 Cr | - | 19.75% | 0.12 |
| Biocon Ltd | - | 110.29 | ₹61,113.53 Cr | 0.13% | ₹416.4 Cr | - | ₹17,321.1 Cr | - | 2.87% | 0.43 |
| Abbott India Ltd | - | 35.22 | ₹56,860.69 Cr | 1.78% | ₹1,614.68 Cr | - | ₹7,004.38 Cr | - | 45.73% | 0 |
| Glaxosmithkline Pharmaceuticals Ltd | - | 46.73 | ₹49,091.33 Cr | 1.97% | ₹1,068.15 Cr | - | ₹3,954.94 Cr | - | 64.07% | 0 |
| Ipca Laboratories Ltd | - | 36.13 | ₹48,712.48 Cr | 0.31% | ₹1,379.76 Cr | - | ₹10,125.58 Cr | - | 21.48% | 0.09 |
| Anthem Biosciences Ltd | - | 83.03 | ₹47,949.68 Cr | 0.23% | ₹575.95 Cr | - | ₹2,002.34 Cr | - | 25.5% | 0.02 |
| Gland Pharma Ltd | - | 42.26 | ₹47,764.08 Cr | 0.69% | ₹1,128.8 Cr | - | ₹6,725.3 Cr | - | 15.21% | 0.02 |
| Ajanta Pharma Ltd | - | 38.87 | ₹44,109.77 Cr | 0.79% | ₹1,134.88 Cr | - | ₹5,776.17 Cr | - | 31.81% | 0.05 |
| J B Chemicals & Pharmaceuticals Ltd | - | 53.3 | ₹38,730.77 Cr | 0.39% | ₹709.46 Cr | - | ₹4,147.79 Cr | - | 23.03% | 0 |
Quarterly Results
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Sales | 514.27 | 439.71 | 776.25 | 641.58 |
| ↳ QoQ Growth | - | -14.5% | +76.5% | -17.3% |
| Expenses | 381.27 | 386.5 | 494.01 | 445.25 |
| Operating Profit | 133 | 53.21 | 282.24 | 196.33 |
| OPM % | 25.86% | 12.1% | 36.36% | 30.6% |
| Other Income | 1.8 | 8.05 | 12.46 | 8.49 |
| Interest | 5.37 | 6.79 | 7.21 | 6.97 |
| Depreciation | 22.54 | 23.92 | 25.09 | 26.56 |
| EBITDA | 155.54 | 77.13 | 307.33 | 222.89 |
| EBITDA Margin % | 30.24% | 17.54% | 39.59% | 34.74% |
| Profit Before Tax | 129.44 | 54.48 | 287.49 | 197.85 |
| Tax % | 25.17% | 25.51% | 26.03% | 25.36% |
| Net Profit | 96.85 | 40.57 | 212.67 | 147.67 |
| ↳ QoQ Growth | - | -58.1% | +424.2% | -30.6% |
| EPS | 75.49 | 31.62 | 165.76 | 115.1 |
Balance Sheet
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 12.9 | 12.9005 |
| Reserves | 1511.91 | 1861.5724 |
| Borrowings | 157.14 | 196.61 |
| Other Liabilities | 497.93 | 859.05 |
| Total Liabilities | 2179.88 | 2930.1377 |
| Fixed Assets | 673.71 | 1178.0144 |
| CWIP | 44.55 | 209.499 |
| Investments | 109.21 | 1.98 |
| Other Assets | 1352.41 | 1540.64 |
| Total Assets | 2179.88 | 2930.1377 |
Cash Flows
| Mar 2026 | |
|---|---|
| Cash from Operating Activity | 346.6804 |
| Cash from Investing Activity | -423.7329 |
| Cash from Financing Activity | 20.9754 |
| Net Cash Flow | -56.0771 |
Shareholding Pattern
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Promoters % | 32.64% | 32.63% | 32.63% | 32.62% |
| FIIs % | 20.6% | 20.9% | 20.46% | 21.08% |
| DIIs % | 13.55% | 14.71% | 15.85% | 16.51% |
| Public % | 24.72% | 24.31% | 23.84% | 22.88% |
| No. of Shareholders | 44,393 | 46,187 | 46,304 | 44,340 |
Major Shareholders (>1%)
- Davuluri Ownership Trust (dr. Davuluri Ramamohan Rao, Mr. Davuluri Sucheth Rao And Mr. Davuluri SahaPromoter and Promoter Group25.98%
- Malabar India Fund LimitedPublic Shareholding5.42%
- Mukul Mahavir AgrawalPublic Shareholding3.12%
- Icici Prudential Balanced Advantage FundPublic Shareholding2.19%
As of 2026-06-30View all shareholders →